Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)

NCT00225992 is registered in ClinicalTrials.gov with Oncology Specialties, Alabama as lead sponsor.

NCT NCT00225992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00225992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
Lead sponsor
Oncology Specialties, Alabama
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2004
Completion date
November 30, 2007
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds)